factor receptor superfamily, is a soluble decoy receptor for the osteoclast differentiation factor receptor-activator of nuclear factor B ligand (RANKL) that inhibits interaction between RANKL and its membrane-bound receptor RANK (Figure) . 1 The RANKL/OPG/RANK axis has been shown to regulate bone remodeling 2, 3 and was more recently found to be involved in carcinogenesis as well as central thermoregulation. 4, 5 This system has also been linked to the development of atherosclerosis and plaque destabilization. 6, 7 RANKL exhibits several properties with relevance to atherogenesis, such as promotion of inflammatory responses in T cells and dendritic cells, induction of chemotactic properties in monocytes, induction of matrix metalloproteinase (MMP) activity in vascular smooth muscle cells (SMC), and RANKL has also been found to have prothrombotic properties. 2, 8 In observational studies, elevated circulating OPG levels have been associated with prevalence and severity of coronary artery disease, cerebrovascular disease, and peripheral vascular disease. 2, 8 Circulating OPG levels are increased in patients with acute coronary syndrome, 9 and enhanced expression has been found within symptomatic carotid plaques. 10 Elevated OPG levels have also been associated with the degree of coronary calcification in the general population as a marker of coronary atherosclerosis. 11 OPG has been reported to predict survival in patients with heart failure after acute myocardial infarction, 12 to predict heart failure hospitalization and mortality in patients with acute coronary syndrome, 9 and to be associated with long-term mortality in patients with ischemic stroke. 13 There are also a few studies that show a relationship between OPG and cardiovascular disease (CVD) and related mortality in the general population. 6, 14 
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In this issue, Lieb et al 15 describe the clinical correlates, from subclinical disease to mortality, of serum OPG in 3250 Framingham study participants. They found that OPG was related to risk factors, such as age, smoking, diabetes, systolic blood pressure, and prevalent CVD, as well as CVD-related mortality. There was also a (nonsignificant) relation between OPG and coronary calcification, and the Dallas heart study demonstrated a relation of OPG to coronary as well as aortic calcifications. 11 In addition, Vik et al 16 have recently shown that OPG was an independent predictor of plaque growth in the general population in women but not in men, indicating gender-specific actions of OPG in plaque progression. Taken together, all these studies suggest that OPG may be a new promising marker for risk prediction in CVD.
On the other hand, although the pathogenic effects of the RANKL/OPG/RANK axis in atherogenesis has been related to RANKL activities ( Figure) , Lieb et al did not find any relation between serum levels of RANKL and CVD, which is in line with the EPIC-Norfolk and the Tromsø studies 14, 16 but not with the Bruneck study. 6 Moreover, genetic OPG inactivation accelerates advanced atherosclerotic lesion progression in older apolipoprotein E Ϫ/Ϫ mice, and OPG treatment promotes SMC accumulation, collagen fiber formation, and development of fibrous caps in apolipoprotein E deficient mice, suggesting a protective rather than harmful effect of OPG in atherogenesis. 8, 17 The reasons for these apparently discrepant findings are at present not clear, but several potential explanations may exist. A reliable biomarker in CVD is not necessarily an important mediator in atherosclerosis but rather a stable marker of up-stream pathways that are involved in the pathogenesis of CVD. In fact, the leading role of C-reactive protein as an inflammatory biomarker in CVD is not primarily based on its pathogenic role in these disorders but rather on its ability to reflect upstream inflammatory activity. OPG has been shown to be modulated by various up-stream inflammatory mediators, such as interleukin 1 and tumor necrosis factor ␣. 18 Moreover, because OPG circulates at much higher levels than RANKL, it may be a more stable overall measure of RANKL/RANK activity than soluble RANKL. Therefore, the role of OPG as a marker in CVD may not be related to its role as a mediator but reflect its role as a stable marker of activity in the RANKL/OPG/RANK axis, as well as the activities in inflammatory pathways that are involved in atherogenesis. Thus, mirroring several interaction pathways with relevance to atherosclerosis, such as inflammation, matrix degradation, and vascular calcification. Moreover, Golledge et al 10 reported OPG to be expressed at higher levels in symptomatic carotid plaques than in asymptomatic carotid plaques, and it is possible that the relation between circulating OPG levels and CVD may, at least in part, reflect shedding from atherosclerotic lesions. However, several questions remain unresolved. First, although OPG is a known inhibitor of RANKL, its biological effect may depend on the molar ratio between RANKL and OPG. 7 Thus, although OPG under low RANKL/OPG ratios attenuates RANKL-mediated effects, it has during high RANKL/OPG ratios been found to enhance the RANKL-mediated effects on MMP levels in vascular SMC. Also, OPG has been shown to exert chemo-tactic properties, and SMC incubated with OPG develop impaired cell proliferation, increased apoptosis, increased MMP-2 and MMP-9 levels, and enhanced interleukin 6 production. 19 Furthermore, in addition to its ability to bind RANKL, OPG seems to also bind tumor necrosis factorrelated apoptosis inducing ligand, 20 but the role of this interaction, with potential antiapoptotic net effects, in atherogenesis has not been studied. Second, in line with some other studies, Lieb et al found an inverse correlation between circulating RANKL and OPG levels. It is important to clarify if OPG and RANKL are differently regulated or if these findings merely reflect enhanced binding of circulating RANKL to OPG in excess of OPG, leading to decreased levels of free RANKL. Moreover, although several studies have suggested a role for RANKL/OPG/RANK axis in atherogenesis, OPG was recently found to inhibit vascular calcification without affecting atherosclerosis in low-density lipoprotein receptor-deficient mice. 21 In the Tromsø study, OPG was associated with plaque progression but not with novel plaque formation, suggesting a restricted role in atherogenesis. 16 Furthermore, drugs targeting the RANKL/OPG/ RANK axis have not been related to CVD events in randomized trials, 22, 23 but importantly, these studies were not designed to evaluate their effect on CVD.
Although several studies suggest the involvement of RANKL/OPG/RANK axis in coronary artery disease and related atherosclerotic disorders, 18, 24 more evidence is needed to evaluate the predictive and diagnostic value of serum OPG levels for clinical use as well as the pathogenic importance of these mediators in the process of atherosclerosis and plaque rupture.
Sources of Funding
This work was supported by the Swedish Research Council and the Swedish Heart Lung foundation (K.C.).
Disclosures
None.
Figure.
A, Regulation of osteoclastogensesis by the RANKL/OPG/RANK axis. Soluble and membrane bound RANKL on osteoblasts stimulate: proliferation into preosteoclasts (1), differentiation to become prefusion osteoclasts (2), fusion into multinucleated bone resorbing osteoclasts (3), and prevent apoptosis of mature osteoclasts (4) . OPG blocks the effects of RANKL by neutralizing and preventing binding to its receptor RANK. B, Sources of RANKL in the vessel wall. Proinflammatory cytokines upregulate soluble or membrane-bound RANKL on: endothelial cells (1), activated T cells (2), vascular SMCs undergoing osteogenic differentiation (3), and endothelial cells in contact with CD-44 expressing vascular SMC (4). C, Function of RANKL in atherosclerotic vascular calcification. RANKL may play a role in the atherosclerotic process through: triggering endothelial cells survival and proliferation (1), stimulating monocyte and lymphocyte transmigration and activation of T cells (2), maturation and activation of dendritic cells (3), increased matrix MMP activity from monocytes and vascular SMC that may promote plaque rupture and thrombus formation (4), and promotion of osteogenesis, leading to synthesis of bone proteins and matrix calcification within the arterial vessel (5) .
